Last update Dec. 21, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Main tradenames from several countries containing Didanosine (DDI) in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 42 ± 12 | % |
Molecular weight | 236 | daltons |
Protein Binding | < 5 | % |
VD | 4 ± 2 | l/Kg |
pKa | 10.9 | - |
Tmax | 0.5 - 1.5 | hours |
T½ | 1.2 ± 0.2 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Antiretroviral. It is a nucleoside reverse transcriptase inhibitor (NRTI) with antiviral activity against HIV-1. Indicated for the treatment of HIV infection and AIDS. Administration together with other oral antiretrovirals in one or two daily doses.
At the date of the last update we did not find any published data on its excretion in breast milk.
It has been used to treat children older than 3 mo of age.
The most common serious adverse effects of didanosine are peripheral neuropathy and life-threatening pancreatitis. Other frequently reported adverse effects are abdominal pain, diarrhea, fatigue, headache, nausea, rash, and vomiting. (Martindale)
During breastfeeding, other HIV/AIDS treatments are preferable. (Panel 2022, WHO 2016)
See below the information of this related product: